Literature DB >> 26393481

Adjuvant and salvage radiation therapy after prostatectomy: investigating beliefs and practices of radiation oncologists.

Marco Lupattelli1, Matthew Alcusky2, Cynthia Aristei3, Rita Bellavita1, Barbara A Jereczek-Fossa4, John McAna2, Timothy N Showalter5, Vittorio Maio2.   

Abstract

OBJECTIVE: Evidence regarding adjuvant radiation therapy (ART) and salvage radiation therapy (SRT) following radical prostatectomy (RP) for prostate cancer is inconsistent. The study objectives were to collect survey information on Italian radiation oncologists' (RO) beliefs regarding the use of ART and SRT following RP and to compare the results of Italian RO with those of American RO available from an analogous survey.
METHODS: A modified version of a US-based questionnaire captured attitudes and clinical approaches regarding post-RP RT of all 716 RO practicing in 147 radiation oncology centres in Italy. Bivariate analyses compared the responses of Italian RO with those of American RO retrieved from a previously published study.
RESULTS: Analysable questionnaires were completed by 153 Italian RO (response rate, 21%). Variations in practice were found for RT use, timing, dosage and technique. All Italian RO supported ART use, although factors influencing the decision to initiate ART varied. Most RO (81%) would wait 3-6 months after surgery before beginning RT. Compared with Italian RO, more American RO believed ART improves survival outcomes (70% vs 35%, p < 0.001), would initiate ART based solely on adverse pathological features (79% vs 69%, p < 0.001) and would initiate SRT based on any detectable prostate-specific antigen (37% vs 11%, p < 0.001).
CONCLUSION: Italian RO strongly supported ART, but their approach to patient selection for ART and SRT varied. Striking differences between Italian RO and American RO regarding ART and SRT practices were found. ADVANCE IN KNOWLEDGE: Differential RT practices and perceptions exist among RO internationally. Clinical studies must inform evidence-based guidelines to harmonize the use of post-RP RT.

Entities:  

Mesh:

Year:  2015        PMID: 26393481      PMCID: PMC4743471          DOI: 10.1259/bjr.20150587

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  24 in total

1.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; F Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-10-06       Impact factor: 20.096

2.  Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study.

Authors:  P J Van Cangh; F Richard; F Lorge; Y Castille; A Moxhon; R Opsomer; L De Visscher; F X Wese; P Scaillet
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

3.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Bertrand Tombal; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Marc Colombel; Cees van de Beek; Paul Verhagen; Alphonsus van den Bergh; Cora Sternberg; Thomas Gasser; Geertjan van Tienhoven; Pierre Scalliet; Karin Haustermans; Laurence Collette
Journal:  Lancet       Date:  2012-10-19       Impact factor: 79.321

4.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

5.  Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen.

Authors:  M S Anscher
Journal:  Int J Cancer       Date:  2001-04-20       Impact factor: 7.396

6.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

7.  Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose.

Authors:  R K Valicenti; L G Gomella; M Ismail; S G Mulholland; S Strup; R O Petersen; B W Corn; J D Lu
Journal:  Urology       Date:  1998-12       Impact factor: 2.649

8.  Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.

Authors:  Ian M Thompson; Richard K Valicenti; Peter Albertsen; Brian J Davis; S Larry Goldenberg; Carol Hahn; Eric Klein; Jeff Michalski; Mack Roach; Oliver Sartor; J Stuart Wolf; Martha M Faraday
Journal:  J Urol       Date:  2013-05-21       Impact factor: 7.450

9.  The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer.

Authors:  F Alongi; B De Bari; P Franco; P Ciammella; T Chekrine; L Livi; B A Jereczek-Fossa; A R Filippi
Journal:  Radiol Med       Date:  2013-01-28       Impact factor: 3.469

10.  Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists.

Authors:  Luke T Lavallée; Dean Fergusson; Ranjeeta Mallick; Renée Grenon; Scott C Morgan; Franco Momoli; Kelsey Witiuk; Chris Morash; Ilias Cagiannos; Rodney H Breau
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.